Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03782402 · ClinicalTrials.gov registry record · Phase 2
Cannabinoids for Taxane Induced Peripheral Neuropathy
A Phase 2 study, sponsored by New York State Psychiatric Institute.
- Terminated
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT03782402 is a Phase 2 study that was terminated before completion, run by New York State Psychiatric Institute. The registered enrollment target is 12 participants.
The verdict
NCT03782402, a Phase 2 study, was terminated before completion, sponsored by New York State Psychiatric Institute.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
Taxane-induced peripheral neuropathy (TIPN) affects a significant number of women undergoing breast cancer treatment. Some patients may need to shorten their course of treatment, and do not receive the full benefit of chemotherapy as a result. Rodent studies have shown that the cannabinoids may significantly improve hyperalgesia and allodynia induced by paclitaxel. The goal of this study is to investigate the cannabinoids THC and CBD for TIPN.
Interventions
- DRUG Cannabinoids
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2019-09-01 |
| Est. Completion | 2021-08-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03782402
The ClinicalTrials.gov registry entry for NCT03782402 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cannabinoids is the first listed.
NCT03782402 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03782402 about?
NCT03782402 is a clinical study titled "Cannabinoids for Taxane Induced Peripheral Neuropathy". Taxane-induced peripheral neuropathy (TIPN) affects a significant number of women undergoing breast cancer treatment. Some patients may need to shorten their course of treatment, and do not receive the full benefit of chemotherapy as a result. Rodent studies have shown that the cannabinoids may sign...
What is the current status of trial NCT03782402?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2019-09-01. Estimated completion is 2021-08-30.
What interventions are being tested in trial NCT03782402?
The interventions under investigation include: Cannabinoids (DRUG).
Who is sponsoring clinical trial NCT03782402?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.